LM11A-31 dihydrochloride

Research use only, not for human use.

An orally available, brain penetrant p75NTR ligand that blocks p75-mediated cell death, also increases proliferation and survival of hippocampal neural progenitors.

An orally available, brain penetrant p75NTR ligand that blocks p75-mediated cell death, also increases proliferation and survival of hippocampal neural progenitors; shows no effect on nerve growth factor (NGF) binding to TrkA; prevents and reverses atrophy of cholinergic neurites, as well as reversing AD pathologies in mid- to late-stage AD mice models.Alzheimer Disease Phase 2 Clinical.

——

LM11A-31 (oral gavage; 50 mg kg/day for 4 weeks) significantly mitigates proNGF accumulation and preserves BRB integrity. LM11A-31 (orally; 50 or 75 mg/kg) administered for 3 months starting at 6-8 months of age prevents and/or reverses atrophy of basal forebrain cholinergic neurites and cortical dystrophic neurites in mid-stage male APPL/S mice. Animal Model:Male C57BL/6 J mice Dosage:50 mg kg/day Administration:Oral gavage; for 4 weeks Result:Mitigated proNGF accumulation and preserved BRB integrity.

LM11A-31 BHS

Tyrosine Kinase

Trk Receptor

Trk Receptor

Neurological Disease

Alzheimer Disease

1243259-19-9

316.27

C12H25N3O2.2HCl

>98% (HPLC)

In Vitro:?H2O : 100 mg/mL (316.19 mM)

CCC(C)C(C(=O)NCCN1CCOCC1)N.Cl.Cl

(2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)pentanamide dihydrochloride

(-20℃)

With Ice Pack

≥ 2 years